Tirasemtiv not found effective for treatment of MND
The MND Research Blog reports that Cytokinetics Inc. has announced in their official press release published on 21 November 2017, that they will not be continuing work on tirasemtiv after disappointing results in the latest Phase 3 clinical trial. The trial, known under the acronym ‘VITALITY-ALS’, tested whether the drug has a beneficial effect on the breathing function and muscle strength of people with MND.